drugset
drugset / Trial / NCT03677401

Study of the Efficacy, Safety and Tolerability of Serlopitant for the Treatment of Pruritus (Itch) With Prurigo Nodularis

NCT03677401 ↗

Phase 3 Completed 295 enrolled Vyne Therapeutics Inc.
RandomizedParallel-groupQuadruple-blindTreatment

Summary

Study of the efficacy, safety, and tolerability of serlopitant for the treatment of pruritus in adults with prurigo nodularis

Timeline

Start
2018-08-29
Primary completion
2020-01-09
Completion
2020-02-06

Outcome

Missed primary endpoint

registry analysis (superiority test); Placebo vs Serlopitant 5 mg; p = 0.158; Cochran-Mantel-Haenszel NCT03677401 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Serlopitant Small molecule 5 mg —

Indications

prurigo prurigo nodularis